Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

In English

Författare

  • S. Lambert-Niclot
  • E.C. George
  • A. Pozniak
  • E. White
  • C. Schwimmer
  • H. Jessen
  • M. Johnson
  • D. Dunn
  • C.F. Perno
  • B. Clotet
  • A. Plettenberg
  • A. Blaxhult
  • L. Palmisano
  • L. Wittkop
  • V. Calvez
  • A.G. Marcelin
  • F. Raffi
  • Nikos Dedes
  • Geneviève Chěne
  • Clotilde Allavena
  • Brigitte Autran
  • Andrea Antinori
  • Raffaella Bucciardini
  • Stefano Vella
  • Andrzej Horban
  • Jose Arribas
  • Abdel G. Babiker
  • Marta Boffito
  • Deenan Pillay
  • Anton Pozniak
  • Xavier Franquet
  • Siegfried Schwarze
  • Jesper Grarup
  • Aurélie Fischer
  • Laura Richert
  • Cédrick Wallet
  • François Raffi
  • Alpha Diallo
  • Jean-Michel Molina
  • Juliette Saillard
  • Christiane Moecklinghoff
  • Hans-Jürgen Stellbrink
  • Remko Van Leeuwen
  • Jose Gatell
  • Eric Sandstrom
  • Markus Flepp
  • Fiona Ewings
  • Elizabeth C. George
  • Fleur Hudson
  • Michal Odermarsky
Visa allt

Summary, in English

Objectives: To describe the pattern of drug resistance at virological failure in the NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either tenofovir/emtricitabine or raltegravir). Methods: Genotypic testing was performed at baseline for reverse transcriptase (RT) and protease genes and for RT, protease and integrase (IN) genes for patients with a confirmed viral load (VL) >50 copies/mL or any single VL >500 copies/mL during or after week 32. Results: A resistance test was obtained for 110/805 (13.7%) randomized participants qualifying for resistance analysis (61/401 of participants in the raltegravir arm and 49/404 of participants in the tenofovir/emtricitabine arm). No resistance-associated mutation (RAM) was observed in the tenofovir/emtricitabine plus darunavir/ritonavir arm, and all further analyses were limited to the raltegravir plus darunavir arm. In this group, 15/55 (27.3%) participants had viruses with IN RAMs (12 N155H alone, 1 N155H + Q148R, 1 F121Y and 1 Y143C), 2/53 (3.8%) with nucleotide analogue RT inhibitor RAMs (K65R, M41L) and 1/57 (1.8%) with primary protease RAM (L76V). The frequency of IN mutations at failure was significantly associated with baseline VL: 7.1% for a VL of TREND = 0.007). Of note, 4/15 participants with IN RAM had a VL <200 copies/mL at time of testing. Conclusions: In the NEAT001/ANRS143 trial, there was no RAM at virological failure in the standard tenofovir/emtricitabine plus darunavir/ritonavir regimen, contrasting with a rate of 29.5% (mostly IN mutations) in the raltegravir plus darunavir/ritonavir NRTI-sparing regimen. The cumulative risk of IN RAM after 96 weeks of follow-up in participants initiating ART with raltegravir plus darunavir/ritonavir was 3.9%.

Publiceringsår

2016-04-01

Språk

Engelska

Sidor

1056-1062

Publikation/Tidskrift/Serie

Journal of Antimicrobial Chemotherapy

Volym

71

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Infectious Medicine

Nyckelord

  • clinical trial
  • controlled clinical trial
  • controlled study
  • follow up
  • gene frequency
  • gene mutation
  • genetic predisposition
  • human
  • major clinical study
  • mutation
  • randomized controlled trial
  • virus load
  • darunavir
  • emtricitabine
  • integrase
  • nucleotide
  • proteinase
  • raltegravir
  • ritonavir
  • RNA directed DNA polymerase
  • tenofovir

Status

Published

Forskningsgrupp

  • Child and Family Health

ISBN/ISSN/Övrigt

  • ISSN: 1460-2091